LeonaBio (LONA) Income from Continuing Operations (2019 - 2026)
LeonaBio (LONA) posted quarterly Income from Continuing Operations of 21108000.0 for Q1 2026, down 96.12% year-over-year from 543505751.2 in Q1 2025, and up 73.81% quarter-over-quarter from 80595000.0 in Q4 2025.
LeonaBio (LONA) Income from Continuing Operations (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Income from Continuing Operations for 8 consecutive years, with 21108000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 96.12% year-over-year to 21108000.0; the TTM figure through Mar 2026 stood at 117954000.0 (up 33.75% YoY), while the FY2025 annual figure was 105610000.0, down 8.98% from the prior year.
- Income from Continuing Operations advanced to 21108000.0 in Q1 2026 per LONA's latest filing, from 80595000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7855000.0 in Q3 2025 and bottomed at 107515000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 33835588.24 across 5 years, with a median of 29401000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 265.68% — and 2025, when it surged 74.74%.
- LeonaBio's Income from Continuing Operations stood at 33323000.0 in 2022, then grew by 11.77% to 29401000.0 in 2023, then slumped by 265.68% to 107515000.0 in 2024, then climbed by 25.04% to 80595000.0 in 2025, then jumped by 73.81% to 21108000.0 in 2026.
- Business Quant data shows LONA's Income from Continuing Operations at 21108000.0 in Q1 2026, 80595000.0 in Q4 2025, and 7855000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - | -19.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.11 Mn |
| Dec 31, 2025 | -80.60 Mn |
| Sep 30, 2025 | -7.86 Mn |
| Jun 30, 2025 | -8.40 Mn |
| Mar 31, 2025 | -10.76 Mn |
| Dec 31, 2024 | -107.52 Mn |
| Sep 30, 2024 | -31.09 Mn |
| Jun 30, 2024 | -28.68 Mn |
| Mar 31, 2024 | -29.40 Mn |
| Dec 31, 2023 | -29.40 Mn |
| Sep 30, 2023 | -36.99 Mn |
| Jun 30, 2023 | -33.71 Mn |
| Mar 31, 2023 | -31.95 Mn |
| Dec 31, 2022 | -33.32 Mn |
| Sep 30, 2022 | -26.54 Mn |
| Jun 30, 2022 | -24.36 Mn |
| Mar 31, 2022 | -33.52 Mn |
| Dec 31, 2021 | -18.78 Mn |
| Sep 30, 2021 | -23.83 Mn |
| Jun 30, 2021 | -24.34 Mn |